An Early Phase 1 interventional study of Neuropeptide Y in Hypertension and Obesity, sponsored by University of Texas Southwestern Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-03.
Sponsored by University of Texas Southwestern Medical Center · Early Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Hypertension by University of Texas Southwestern Medical Center — 7 open to participants now, 7 under way, none of them phase 3. Hypertension · University of Texas Southwestern Medical Center.
Among the 31 studies in Hypertension by University of Texas Southwestern Medical Center, this one is the 11th largest by planned enrollment of the 27 interventional ones that give a count, is the only one that started in 2021, is one of 2 in phase 1, and was the 23rd registered.
6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.
Browse Hypertension studies →7 of the 31 studies in Hypertension by University of Texas Southwestern Medical Center are open now, in 1 country. Recruiting first, the newest first:
University of Texas Southwestern Medical Center · Sites in United States
Ages 18–100
University of Texas Southwestern Medical Center · Sites in United States
Ages 18+ · Women only · Healthy volunteers
University of Texas Southwestern Medical Center · Sites in United States
Ages 18–60
University of Texas Southwestern Medical Center · Sites in United States
Ages 70+
University of Texas Southwestern Medical Center · Sites in United States
Ages 18–75
By country, each count listing its studies:
Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 8 · Phase 3 1 · Phase 4 6
First in 2005; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is close to the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 85 across the 27 interventional studies, 77 across the 4 observational. Of the 23 that completed or were terminated, 12 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Texas Southwestern Medical Center is the lead sponsor of 1,012 studies on the registry; 200 are open to participants now.
Of its 139 completed or terminated interventional studies of FDA-regulated products, 105 (76%) have results posted.
4 of the studies in Hypertension by University of Texas Southwestern Medical Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04838678University of Texas Southwestern Medical CenterSympathetic Transduction in Obesity-associated Hypertension (OB-HTN) | 2026-12-31 |
| NCT05168605University of Texas Southwestern Medical CenterAssessing the Efficacy of Targeted Home Visits in the Management of Chronic Conditions | 2026-12-31 |
| NCT06218355University of Texas Southwestern Medical CenterIMPACT: Improving Maternal Postpartum Access to Care Through Telemedicine | 2027-09-01 |
| NCT06143566University of Texas Southwestern Medical CenterPolypill for Prevention of Cardiomyopathy | 2027-09-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 31 studies in Hypertension by University of Texas Southwestern Medical Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to understand how the nervous system communicates to blood vessels to increase blood pressure during stress. The study will also investigate how hypertension and obesity influence the nervous system and vascular function. The study will involve measuring sympathetic nervous system activity and blood flow during common laboratory physiological stress protocols (e.g. hypoxia, exercise), and in response to infusion of drugs that cause vasodilation or vasoconstriction.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
All groups - presence of other significant cardiovascular disease, renal disease, history of smoking, diabetes,
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy age matched controls with no history of cardiovascular disease and normal bodyweight
Drug: Neuropeptide Y
Hypertensive adults who are not obese
Drug: Neuropeptide Y
Obese adults who are not hypertensive
Drug: Neuropeptide Y
Obese adults who are being treated for hypertension
Drug: Neuropeptide Y
intra-arterial infusion of neuropeptide Y
Blood flow measured by doppler ultrasound
brachial and femoral artery blood flow
Time frame: Acutely on the day of study
Muscle sympathetic nervous system activity
recording of sympathetic nervous system activity from the peroneal or radial nerve
Time frame: Acutely on the day of study
Started Jul 2021 (actual). Primary completion is estimated for Dec 2026, 65 months after the start.
Of 44 non-industry phase 1 interventional studies under Hypertension, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 12. This study's planned 65 months is above that.
Counting every sponsor, half of 176 studies reached it within 4 months; a quarter within 1 and three quarters within 18.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Neuropeptide Y
University of Texas Southwestern Medical Center →